{"nctId":"NCT00986154","briefTitle":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","startDateStruct":{"date":"2009-10"},"conditions":["Venous Thromboembolism","Deep Vein Thrombosis (DVT)","Pulmonary Embolism (PE)","Thromboembolism","Venous Thrombosis"],"count":8292,"armGroups":[{"label":"heparin/edoxaban tosylate","type":"EXPERIMENTAL","interventionNames":["Drug: edoxaban tosylate(DU-176b)","Drug: low molecular weight heparin/unfractionated heparin"]},{"label":"heparin/warfarin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: low molecular weight heparin/unfractionated heparin","Drug: warfarin"]}],"interventions":[{"name":"edoxaban tosylate(DU-176b)","otherNames":[]},{"name":"low molecular weight heparin/unfractionated heparin","otherNames":[]},{"name":"warfarin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects older than the minimum legal adult age (country specific);\n* Acute symptomatic proximal DVT and/or symptomatic PE confirmed at the site by appropriate diagnostic imaging;\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE;\n* More than 48 hours pre-treatment with anticoagulant therapy prior to randomization;\n* Calculated Creatinine clearance (CrCL) \\< 30 mL/min;\n* significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \\>\\\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN;\n* patients with active cancer for whom long term treatment with (LMW) heparin is anticipated;\n* active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin or warfarin;\n* chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs);\n* treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet therapy;\n* concurrent treatment with potent P-gp inhibitors;\n* subjects with any condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE","description":"Symptomatic recurrent Venous Thromboembolism (VTE), i.e., the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE occurring during the Overall Study Period.\n\nOverall Study Period defined as \"The time from the reference date (randomization date/initial dose of study drug date) to the last study follow-up visit.\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Clinical Outcome of Symptomatic Recurrent VTE and All-cause Mortality","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Relevant Bleeding (i.e., Major or Clinically Relevant Non-major Bleeding) Occurring During Treatment","description":"Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding) occurring during treatment plus 3 days after their last dose for that time period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349","spread":null},{"groupId":"OG001","value":"423","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":801,"n":4118},"commonTop":["nasopharyngitis","headache","epistaxis","pain in extremity","international normalised ratio increased"]}}}